RxDoctor Payments Data

Scott Phillips, MD

Internal Medicine · Pittsburgh, PANPI 1003840513

Payments from drug & device makers

$17,229in general payments, 2019–2025

Across 998 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • Pfizer$2K
  • Boehringer Ingelheim$2K
  • AbbVie$1K
  • plus $7K from 35 others

What the payments were for

  • Food & beverage$17,191100%
  • Education$380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$17,229 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$64,897
Medicare patients
142
Services billed
881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin106$97,280
MounjaroTirzepatide43$48,221
EliquisApixaban41$31,906
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$25,715
TradjentaLinagliptin15$22,677
JanuviaSitagliptin Phosphate33$21,183
MyrbetriqMirabegron33$18,908
FarxigaDapagliflozin Propanediol26$17,634
OzempicSemaglutide13$12,375
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$9,761
XareltoRivaroxaban14$8,413
LinzessLinaclotide13$7,289
Breo ElliptaFluticasone/Vilanterol17$6,754
Levothyroxine Sodium457$3,228
Boostrix TdapDiphth,pertuss(Acell),tet Vac43$2,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$1,655$119,957121 claims
Lilly USA, LLCMounjaro$1,865$48,22143 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$2,213$42,23078 claims
PfizerEliquis$1,781$31,90641 claims
MerckJanuvia, Asmanex$856$22,09644 claims
Astellas Pharma US IncMyrbetriq$229$18,90833 claims
AstraZenecaFarxiga$870$17,63426 claims
Novo NordiskOzempic$1,875$12,37513 claims
Johnson & JohnsonXarelto$965$8,41314 claims
AbbVieLinzess, Synthroid$1,043$8,31947 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →